In a September 22, 2026 order resolving Regulation Systems Compliance and Integrity violations, the Securities and Exchange Commission censured OTC Link LLC, the registered broker-dealer operating OTC Link ATS, and imposed a $575,000 civil penalty. The order bears Exchange Act Release No. 106458 and Administrative Proceeding File No. 3-22748.
The SEC determined that public administrative and cease-and-desist proceedings against the company were appropriate and in the public interest under Sections 15(b)(4) and 21C of the Securities Exchange Act of 1934. Before those proceedings began, OTC Link LLC submitted a settlement offer that the Commission accepted. The company agreed to the order without admitting the findings, except that it admitted the Commission's jurisdiction over the respondent and the proceedings' subject matter. Its consent was limited to these proceedings and other proceedings brought by or on behalf of the Commission, or in which the Commission is a party. The findings arose from the settlement offer and do not bind any other person or entity in these or other proceedings.
The respondent and the findings
OTC Link LLC is a Delaware limited liability company whose principal place of business is New York, New York. It is wholly owned indirectly by OTC Markets Group Inc. and has been registered with the SEC as a broker-dealer since 2012. It operates five alternative trading system platforms, including OTC Link ATS. Its parent's securities trade over the counter on those platforms under the symbol OTCM.
In 2012, OTC Link ATS notified the Commission of its ATS operations by submitting an Initial Operation Report on Form ATS. The platform also operates as a Qualified Interdealer Quotation System. It is neither a national securities exchange nor a self-regulatory organization.
The SEC described repeated compliance failures involving OTC Link ATS, an alternative trading system for over-the-counter securities. The order identifies the platform as an SCI entity under Regulation SCI and says it held that status throughout the relevant period, August 2016 through March 2025.
Throughout that period, the Commission found, OTC Link LLC lacked reasonably designed written policies and procedures addressing the operational standards Regulation SCI requires. Those standards concern whether SCI systems have adequate capacity, integrity, resilience, availability and security to support the platform's operations and fair and orderly markets. Indirect SCI systems are also covered for security purposes. SEC examinations repeatedly identified deficiencies, but the company did not correct all of them during the relevant period.
The Commission found willful violations of Regulation SCI Rules 1001(a)(1), (a)(2) and (a)(3). For relief under Exchange Act Section 15(b)(4), the order explains, willfulness requires awareness of one's conduct, without requiring awareness that the conduct violates a rule or statute. It cites Wonsover v. SEC, 205 F.3d 408, 414 (D.C. Cir. 2000), quoting Hughes v. SEC, 174 F.2d 969, 977 (D.C. Cir. 1949), and Tager v. SEC, 344 F.2d 5, 8 (2d Cir. 1965).
The order also explains that The Robare Group, Ltd. v. SEC, 922 F.3d 468, 478-79 (D.C. Cir. 2019), does not change that standard. That decision addressed willfulness under a differently structured provision: Section 207 of the Advisers Act, concerning the willful omission of material information from a required disclosure.
Regulation SCI's requirements
The SEC adopted Regulation SCI in 2014 to strengthen the technology supporting U.S. securities markets and advance its mandate to maintain fair and orderly markets. Requirements imposed on certain key market participants were intended to make systems problems less frequent and improve resilience when problems occurred. For that background, the order cites the earlier SCI Adopting Release, Regulation Systems Compliance and Integrity, Securities Exchange Act Release No. 73639, 79 Fed. Reg. 72252, 72257 (December 5, 2014).
As the order recounts, the adopting release recognized that changes in regulation and related technology had increased automated systems' exposure to failures, interruptions, delays and intrusions. The speed of U.S. securities markets and the connections among them meant that even a small problem at one entity could quickly produce losses and liability, spread through the national market system and cause widespread harm, including to investors. Regulation SCI sought to reduce those technological vulnerabilities and strengthen SEC oversight of key market entities' core technology. The order cites pages 72252-53 of the adopting release for those concerns and page 72253 for that objective.
SCI entities are participants with significant roles in U.S. securities markets, the potential to affect investors, markets or individual securities trading through certain systems problems, or both. They include specified self-regulatory organizations, alternative trading systems, plan processors and exempt clearing agencies. The order attributes that description to page 72258 of the adopting release.
Rule 1000, codified at 17 C.F.R. § 242.1000, provides two ways for an ATS to qualify as an SCI ATS. Under the route relevant to this order, a system meeting the ATS definition in 17 C.F.R. § 242.300(a) must reach a specified trading-volume threshold in at least four of the previous six calendar months. For equity securities that are not NMS stocks and whose transactions are reported to a self-regulatory organization, that threshold is at least five percent of average daily dollar volume, calculated by the organization receiving the transaction reports.
Rule 1001(a)(1), at 17 C.F.R. § 242.1001(a)(1), requires SCI entities to put reasonably designed written policies and procedures into effect, maintain them and enforce them. These must support sufficient systems capacity, integrity, resilience, availability and security for continued operational capability and fair and orderly markets. The requirement applies to SCI systems and, for security standards, indirect SCI systems.
Rule 1001(a)(2), at 17 C.F.R. § 242.1001(a)(2), specifies subjects those written policies and procedures must address at a minimum. They include planning for technological infrastructure capacity and stress-testing that capacity; reviewing how systems are developed and tested; assessing vulnerabilities and threats; preparing for business continuity and disaster recovery; collecting and distributing market data; and monitoring for SCI events.
Within those minimum requirements, Rule 1001(a)(2)(iv), at 17 C.F.R. § 242.1001(a)(2)(iv), requires policies and procedures for recurring reviews and tests of SCI systems, including backups. Those reviews and tests must identify vulnerabilities involving threats from inside or outside the entity, physical hazards, and disasters caused by nature or people. Rule 1001(a)(3), at 17 C.F.R. § 242.1001(a)(3), separately requires periodic assessments of the effectiveness of the policies and procedures required under Rule 1001(a), followed by prompt correction of deficiencies.
Deficiencies identified through examinations
The Commission found that, throughout the relevant period, OTC Link LLC failed to put in place, maintain and enforce certain written policies and procedures required by Rule 1001(a)(1). The shortcomings included system-security provisions addressing account management, access controls, security configurations for network devices and prevention of data loss. Those examples were not an exhaustive list.
The company also failed throughout the period to implement, maintain and enforce certain minimum written policies and procedures required by Rule 1001(a)(2). Among the deficiencies were provisions for vulnerability reviews and testing under Rule 1001(a)(2)(iv), including management of application vulnerabilities, testing and remediation. Some documents remained drafts throughout the relevant period.
The SEC's Division of Examinations inspected OTC Link ATS several times during that period. After every examination, staff sent the respondent a letter identifying these and other deficiencies as apparent violations of Rules 1001(a)(1) and (a)(2). The company repeatedly failed to correct apparent violations expressly described in those letters, and subsequent examinations found previously identified policy and procedure deficiencies still unresolved.
The order illustrates that pattern with the platform's access control policy. During an examination in fiscal year 2016, staff identified the policy's draft status as a deficiency. It remained a draft when staff cited it again in deficiency letters issued in 2019 and 2022. As of fiscal year 2023, OTC Link ATS still had not formally established the policy. The Commission found that the company's failure to address deficiencies promptly also violated Rule 1001(a)(3).
In 2024, OTC Link LLC hired outside compliance consultants to assess OTC Link ATS's Regulation SCI compliance program and recommend policies and procedures. In connection with that review, the company has established additional required written policies and procedures since March 2025. They include provisions for managing application vulnerabilities, managing accounts and access controls, and managing network device configurations, subjects for which the company previously had failed to establish, maintain and enforce the required provisions.
Sanctions and payment requirements
The Commission determined that the sanctions accepted in OTC Link LLC's settlement offer were appropriate and in the public interest. Exercising its authority under Exchange Act Sections 15(b)(4) and 21C, it censured the company and directed it to cease and desist from committing or causing violations, including future violations, of Regulation SCI Rules 1001(a)(1), (a)(2) and (a)(3).
The order requires OTC Link LLC to pay the SEC a $575,000 civil money penalty within 14 days after entry of the order. The payment is for transfer to the U.S. Treasury's general fund, subject to Exchange Act Section 21F(g)(3). Late payment triggers additional interest under 31 U.S.C. § 3717.
The company may pay electronically using ACH transfer or Fedwire instructions available from the Commission on request. It may instead pay directly from a bank account through Pay.gov using the SEC payment webpage identified in the order. A third option is a certified check, bank cashier's check or United States postal money order payable to the Securities and Exchange Commission.
A check or money order must be delivered by hand or mail to Enterprise Services Center, Accounts Receivable Branch, HQ Bldg., Room 181, AMZ-341, 6500 South MacArthur Boulevard, Oklahoma City, OK 73169. It must be accompanied by a cover letter identifying OTC Link LLC as a respondent and specifying the proceeding's file number. Copies of both the letter and the check or money order must also be sent to Laura D'Allaird, Chief, Cyber and Emerging Technologies Unit, Division of Enforcement, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549.
For all purposes, including taxation, the civil money penalty must be treated as a penalty paid to the government. To preserve its deterrent effect, OTC Link LLC agreed that it would neither claim entitlement to nor receive the benefit of reducing a compensatory damages award in a Related Investor Action by any portion of the civil penalty paid in this proceeding. The order calls such a reduction a Penalty Offset.
If a court grants a Penalty Offset in a Related Investor Action, the company must both notify the Commission's counsel in this action and pay the SEC the amount of that offset within 30 days after entry of the final order granting it. That payment would not constitute an additional civil penalty or change the penalty imposed in this proceeding. For this provision, a Related Investor Action is a private damages suit against OTC Link LLC, brought by or on behalf of one or more investors, based on substantially the same facts alleged in the Commission's order.
The Commission's order identifies Vanessa A. Countryman as Secretary.

